Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma
This trial demonstrates that Ag-scaffold-driven expansion of TAA-specific T cells from the peripheral blood of patients with MM is feasible, and the resulting MASE-T infusion product can be safely administered. However, further development is required to unleash the full potential of this technology.
Authors
- Rikke B. Holmstroem
- Marcus Svensson (ORCID: https://orcid.org/0000-0002-3934-464X)
- Sine Reker Hadrup (ORCID: https://orcid.org/0000-0002-5937-4344)
- Tine Monberg (ORCID: https://orcid.org/0000-0002-7217-2974)
- Julie Westerlin Kjeldsen (ORCID: https://orcid.org/0000-0001-6201-1758)
- Troels Holz Borch (ORCID: https://orcid.org/0000-0002-4402-9281)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Joachim Stoltenborg Granhøj (ORCID: https://orcid.org/0000-0002-3382-0852)
- Maria Ormhøj (ORCID: https://orcid.org/0000-0002-0997-8262)
- Christian Vestergaard (ORCID: https://orcid.org/0000-0001-6485-3158)
- Özcan Met (ORCID: https://orcid.org/0000-0002-1379-2647)
- Stine Kiær Larsen
- Nithiyashri Jayashankar
- Anne R. Cordt
- Siri Tvingsholm (ORCID: https://orcid.org/0000-0003-1232-139X)
Institutions
- Herlev Hospital (DK)
- BioInnovation Institute (DK)
- Technical University of Denmark (DK)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1016/j.iotech.2025.101581
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00